Medline Inc. (MDLN) Earnings Call Transcripts

Medline Inc.'s Latest Earnings Call - June 9, 2026

In the Q2 2026 earnings call, Medline Inc. reported strong organic revenue growth of 10% and overall growth of 11%, prompting management to raise full-year organic sales guidance to 8.5% to 9.5%. The company addressed concerns regarding a recent FDA warning letter related to quality issues at its ReadyCare facility, emphasizing that the situation was anticipated and manageable. Despite the quality remediation efforts, management remains confident in their operational performance and market demand, signaling a positive outlook for the remainder of the fiscal year.

Reported metrics

Guidance from management

Management raised full-year organic sales guidance to 8.5% to 9.5%, reflecting confidence in demand and market share capture despite potential softness in hospital purchasing later in the year.

What management said

Yes. Every recall we've had has been voluntary, meaning we did it to ourselves. And part of that is a rigor in inspecting yourself. So we have a responsibility as an organization as a manufacturer to make sure that you're inspecting yourself as if the FDA was doing it. So the FDA is not dictating that we recall, we report to the FDA that we are recalling and then we work with the FDA on the remediation efforts as it ...

It depends on the product category. In the surgical [ drapes ] and gallons, we literally displaced it almost immediately, right? We discontinued manufacturing with one of our suppliers. Moved it to another supplier, we're able to fulfill customers' demand. So that was almost a nonimpact to the market. In terms of the [ ReadyCare ] [ Waka ], we actually shut the factory down and we are not producing, we will not produ...

What analysts pressed on

Analysts expressed concerns regarding the potential impact of the FDA warning letter on operations and the financial implications of quality remediation efforts. There were also questions about how the company plans to manage costs amidst rising inflation and tariffs in the second half of the year.

Main topics on the call

• Quality Remediation and FDA Warning Letter — Management acknowledged a recent FDA warning letter regarding quality issues at the ReadyCare facility but stated, "the warning letter was not a surprise as anticipated." They emphasized their proactive approach to quali...
• Revenue Growth and Guidance Increase — Medline reported organic revenue growth of 10% and overall growth of 11%, leading to an increase in full-year organic sales guidance to 8.5% to 9.5%. Management noted, "Demand levels remain strong," which supports their ...
• Impact of Tariffs and Cost Management — Management discussed the burden of tariffs in the first half of the year but expects a favorable impact in the second half due to a reduction in tariff rates. They stated, "tariff favorability will be a net positive for ...
• Market Dynamics and Share Gains — Management highlighted that despite potential softness in hospital purchasing, they are capturing market share, stating, "the outsized growth in the first quarter was tied to sales growth outpacing what we predicted." Th...

Read the full Medline Inc. transcript (June 9, 2026) → Summary generated from the call transcript; every figure above is stated by management on the record.

Earnings Call History

EarningsCalls.dev has 6 Medline Inc. earnings call transcripts on record, spanning January 13, 2026 to June 9, 2026. Based on this history, Medline Inc. reports quarterly. The most recent call on file is dated June 9, 2026. The full list is below — each row opens the complete, free-to-read transcript.

Ticker

MDLN

Exchange

NasdaqGS

Country

US

Sector

Health Care

Industry

Health Care Equipment and Supplies

Calls on record

6

First call

January 13, 2026

Most recent

June 9, 2026

Reporting cadence

quarterly